查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
多重抗藥性細菌感染疾病治療的全球市場:成長，未來預測，競爭分析(2022年～2030年)
市場調查報告書
商品編碼
1180683

多重抗藥性細菌感染疾病治療的全球市場:成長，未來預測，競爭分析(2022年～2030年)

Multiple Drug Resistance Bacterial Infection Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 116 Pages | 商品交期: 最快1-2個工作天內

價格

抗生素耐藥性的上升和對抗現有耐藥性的有前途的管道是多重耐藥性感染治療市場的增長動力。

本報告提供全球多重抗藥性細菌感染疾病治療市場相關調查分析，提供市場趨勢，競爭分析，市場動態，各市場區隔·各地區的市場分析，企業簡介等系統性資訊。

目錄

第1章 序文

第2章 摘要整理

第3章 多重抗藥性細菌感染疾病治療市場:競爭分析

  • 主要的多重抗藥性細菌感染疾病治療市場供應商的市場定位
  • 多重抗藥性細菌感染疾病治療市場供應商僱用的策略
  • 主要的產業策略
  • 階層分析:2021年對2030年

第4章 多重抗藥性細菌感染疾病治療市場:常量分析和市場動態

  • 簡介
  • 全球多重抗藥性細菌感染疾病治療的市場價值(2020年～2030年)
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 主要課題
    • 主要機會
  • 促進因素與阻礙因素的影響分析
  • Seesaw分析

第5章 按多重抗藥性細菌感染疾病治療市場:媒介(2020年～2030年)

  • 市場概要
  • 成長·收益分析:2021年對2030年
  • 市場明細
    • 嚴重
    • 中度
    • 高度

第6章 多重抗藥性細菌感染疾病治療市場:各類藥物(2020年～2030年)

  • 市場概要
  • 成長·收益分析:2021年對2030年
  • 市場明細
    • 頭孢菌素
    • β-內醯胺
    • β-內醯胺酶抑制劑
    • Oxazolidinone
    • 環狀脂肽
    • 糖脂肽
    • 其他

第7章 北美的多重抗藥性細菌感染疾病治療市場(2020年～2030年)

  • 市場概要
  • 各媒介(2020年～2030年)
  • 各類藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 北美

第8章 英國·EU的多重抗藥性細菌感染疾病治療市場(2020年～2030年)

  • 市場概要
  • 各媒介(2020年～2030年)
  • 各類藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 英國·EU

第9章 亞太地區的多重抗藥性細菌感染疾病治療市場(2020年～2030年)

  • 市場概要
  • 各媒介(2020年～2030年)
  • 各類藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 亞太地區

第10章 南美的多重抗藥性細菌感染疾病治療市場(2020年～2030年)

  • 市場概要
  • 各媒介(2020年～2030年)
  • 各類藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 南美

第11章 中東·非洲的多重抗藥性細菌感染疾病治療市場(2020年～2030年)

  • 市場概要
  • 各媒介(2020年～2030年)
  • 各類藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 中東·非洲

第12章 企業簡介

  • Abbott Laboratories, Inc.
  • Actelion Pharmaceuticals Ltd.
  • Albany Molecular Research, Inc.
  • Allergan plc.
  • AstraZeneca
  • Bayer AG
  • Biocon
  • Daiichi Sankyo Company
  • GlaxoSmithKline plc.
  • Macrolide Pharmaceuticals, Inc.
  • Merck & Co, Inc.
  • Pfizer, Inc.
  • Sanofi
  • Teva Pharmaceuticals Industries Ltd.
  • Wockhardt
  • Zavante Therapeutics, Inc.
  • 其他
Product Code: 137601-08-22

This report on global multiple drug resistance bacterial infection treatment market studies various vectors and drug class. Rising prevalence of antimicrobial drug resistance and increasing demand for rapid diagnostic testing kits will propel the multiple drug resistance bacterial infection treatment market growth. The limiting factors related to this market are the complex regulatory approvals for the antibiotics which varies according to countries. Promising pipeline of novel antibiotics with more effective mechanism of action to counteract drug resistance by microbes will result into deep market penetration of the multiple drug resistance bacterial infection treatment market.

For the purpose of this study, the vectors studied include critical, high and medium ; drug class studied for the purpose of this research are segmented as cephalosporins, beta lactams, beta lactamase inhibitors, oxazolidinone, cyclic lipopeptide, glycolipopeptides and others.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global multiple drug resistance bacterial infection treatment market. Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global multiple drug resistance bacterial infection treatment market. The key players profiled in this report are Abbott Laboratories, Inc., Actelion Pharmaceuticals Ltd., Albany Molecular Research, Inc., Allergan plc, AstraZeneca, Bayer AG, Biocon, Daiichi Sankyo Company, GlaxoSmithKline plc, Macrolide Pharmaceuticals, Inc., Merck & Co, Inc., Pfizer, Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Wockhardt, Zavante Therapeutics, Inc., and other notable players.

Antibiotic resistance is accelerated by the misuse and overuse of antibiotics, as well as poor infection prevention and control. World Health Organization (WHO) 2015 awareness guidelines suggest that in order to prevent and control antibiotic resistance use only the prescribed antibiotics, never share or use leftover antibiotics and prevent infection by maintaining personal hygiene, consumption of hygienic food and water, practice safe sex and keep vaccination up to date. The factors responsible for the growth of the multiple drug resistance bacterial infection treatment market are, rising prevalence of antibiotic resistance and promising pipeline to counteract existing drug resistance. In 2016 the beta Lactam drugs held the largest market due to factors such as rising prevalence of Enterobacteriaceae and Pseudomonas aeruginosa carbapenem resistance, and broad spectrum activity delivered by beta lactam drugs such as Ceftazidime-avibactam and Doripenem. Oxazolidinone and Glycolipopeptides will be the fastest growing segments throughout the forecast period 2017-2025, majorly due to factors such as increasing patient pool suffering with Enterococcus faecium and Staphylococcus aureus methicillin and vancomycin resistance, improved pharmacodynamic activity shown by drugs such as Linezolid and Dalbavancin. Overall, the global multiple drug resistance bacterial infection treatment market is highly competitive with presence of multiple players like Abbott Laboratories, Inc., Actelion Pharmaceuticals Ltd., Albany Molecular Research, Inc., Allergan plc, AstraZeneca, Bayer AG, Biocon, Daiichi Sankyo Company, GlaxoSmithKline plc, Macrolide Pharmaceuticals, Inc., Merck & Co, Inc., Pfizer, Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Wockhardt, Zavante Therapeutics, Inc., and other notable players etc. specializing in respective fields. Consolidation activities are being increasingly witnessed on the competitive front with a view to increase the novel antibiotics to counteract drug resistance and better pharmacokinetic activities for better patient compliance and available at low cost.

As per the Assistant Secretary for Preparedness and Response (ASPR) 2015 report of Department of Health and Human Services over the past 15 years there has been 15 entries and 36 corporate exits involved in the antimicrobial treatment. In 2016, the critical vector segment held the largest market in the multiple drug resistance bacterial infection treatment market chiefly due to factors such as rising prevalence of Enterobacteriaceae and Pseudomonas aeruginosa Carbapenem resistance cases and lack of novel drug launch in the Beta lactam antibiotics will serve great opportunity for budding industries to reclaim new grounds to fortify their product portfolio. High segment will be the fastest growing market throughout the forecast period 2017-2025, due to the extensive growth in the Helicobacter pylori (clarithromycin-resistant), and Staphylococcus aureus, (methicillin-resistant, vancomycin-intermediate and resistant) infections and recent launch of novel drug formulation Pylera used to overcome clarithromycin resistance in peptic ulcer treatment; drugs such as linezolid, Daptomycin and Dalvabancin has effective mechanism of action in comparison to vancomycin in the antibiotic resistance treatment.

North America was observed as the largest market for multiple drug resistance bacterial infection treatment market in the base year 2021. According to Department of Health and Human Services of CDC report 2015 approximately 23,000 Americans die each year due to antimicrobial drug resistance; the growth is attributed mainly due to rising prevalence of multiple drug resistance cases, evolved health infrastructure and affordable reimbursement scenario. According to the European Centre for Disease Prevention and Control approximately 25,000 deaths were associated with multidrug resistant bacterial infection; the growth is chiefly attributed due to high public awareness regarding multiple drug resistance leading to early diagnosis and treatment, and supportive regulatory approval for launch of new antibiotics for the treatment of multiple drug resistance. Asia Pacific will be the fastest growing regional segment throughout the forecast period 2022-2030, the growth is attributed by factors like rising prevalence of geriatric population suffering with multiple drug resistance bacterial infection and increasing disposable income in these regions. Factors such as developing health infrastructure, increasing awareness regarding the judicious use of prescribed antibiotics especially in the remote areas are going to fuel the rapid growth of multiple drug resistance bacterial infection treatment market in Latin America and Middle East and Africa region in the near future.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Multiple Drug Resistance Bacterial Infection Treatment market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Multiple Drug Resistance Bacterial Infection Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Vector

Critical

Acinetobacter baumanni (Carbapenem-Resistant)

Pseudomonas aeruginosa (Carbapenem-Resistant)

Enterobacteriaceae (Carbapenem-Resistant)

Medium

Enterococcus faecium (Vancomycin-Resistant)

Helicobacter pylori (Clarithromycin-Resistant)

Staphylococcus aureus (Methicillin-Resistant, Vancomycin Intermediate And Resistant)

Neisseria gonorrhea (Cephalosporin-Resistant, Fluoroquinolone-Resistant)

High

Streptococcus pneumonia (Penicillin-Non-Susceptible)

Haemophilus influenza (Ampicillin-Resistant)

Shigella spp. (Fluoroquinolone-Resistant)

Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)

Drug Class

Cephalosporin

Cefixime (3rd Generation)

Ceftriaxone (3rd Generation)

Ceftobiprole (5th Generation)

Beta Lactam

Doripenem

Imipenem

Meropenem

Ceftazidime

Beta Lactamase Inhibitors

Sulbactam

Tazobactum

Avibactum

Clavam

Oxazolidinone

Linezolid

Cyclic Lipopeptide

Daptomycin

Glycolipopeptides

Dalbavancin

Vancomycin

Others

Polymixins

Tetracycline and Derivatives

Penicillins

Macrolides

Macrolide-Lincosamide-Streptogramin

Rifamycins

Fluoroquinolones

Nitroimidazole

Bismuth Subcitrate Potassium

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of Covid-19 Segment (2020-2021; US$ Million )

Pre Covid-19 situation

Post Covid-19 situation

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Multiple Drug Resistance Bacterial Infection Treatment market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Multiple Drug Resistance Bacterial Infection Treatment market?

Which is the largest regional market for Multiple Drug Resistance Bacterial Infection Treatment market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Multiple Drug Resistance Bacterial Infection Treatment market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Multiple Drug Resistance Bacterial Infection Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Multiple Drug Resistance Bacterial Infection Treatment Market
  • 2.2. Global Multiple Drug Resistance Bacterial Infection Treatment Market, By Vector, 2021 (US$ Million)
  • 2.3. Global Multiple Drug Resistance Bacterial Infection Treatment Market, By Drug Class, 2021 (US$ Million)
  • 2.4. Global Multiple Drug Resistance Bacterial Infection Treatment Market, By Geography, 2021 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2021

3. Multiple Drug Resistance Bacterial Infection Treatment Market: Competitive Analysis

  • 3.1. Market Positioning of Key Multiple Drug Resistance Bacterial Infection Treatment Market Vendors
  • 3.2. Strategies Adopted by Multiple Drug Resistance Bacterial Infection Treatment Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Multiple Drug Resistance Bacterial Infection Treatment Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Multiple Drug Resistance Bacterial Infection Treatment Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Critical
      • 5.3.1.1. Acinetobacter baumanni (Carbapenem-Resistant)
      • 5.3.1.2. Pseudomonas aeruginosa (Carbapenem-Resistant)
      • 5.3.1.3. Enterobacteriaceae (Carbapenem-Resistant)
    • 5.3.2. Medium
      • 5.3.2.1. Enterococcus faecium (Vancomycin-Resistant)
      • 5.3.2.2. Helicobacter pylori (Clarithromycin-Resistant)
      • 5.3.2.3. Staphylococcus aureus (Methicillin-Resistant, Vancomycin Intermediate And Resistant)
      • 5.3.2.4. Neisseria gonorrhea (Cephalosporin-Resistant, Fluoroquinolone-Resistant)
    • 5.3.3. High
      • 5.3.3.1. Streptococcus pneumonia (Penicillin-Non-Susceptible)
      • 5.3.3.2. Haemophilus influenza (Ampicillin-Resistant)
      • 5.3.3.3. Shigella spp. (Fluoroquinolone-Resistant)
      • 5.3.3.4. Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)

6. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 6.3. Market Segmentation
    • 6.3.1. Cephalosporin
      • 6.3.1.1. Cefixime (3rd Generation)
      • 6.3.1.2. Ceftriaxone (3rd Generation)
      • 6.3.1.3. Ceftobiprole (5th Generation)
    • 6.3.2. Beta Lactam
      • 6.3.2.1. Doripenem
      • 6.3.2.2. Imipenem
      • 6.3.2.3. Meropenem
      • 6.3.2.4. Ceftazidime
    • 6.3.3. Beta Lactamase Inhibitors
      • 6.3.3.1. Sulbactam
      • 6.3.3.2. Tazobactum
      • 6.3.3.3. Avibactum
      • 6.3.3.4. Clavam
    • 6.3.4. Oxazolidinone
      • 6.3.4.1. Linezolid
    • 6.3.5. Cyclic Lipopeptide
      • 6.3.5.1. Daptomycin
    • 6.3.6. Glycolipopeptides
      • 6.3.6.1. Dalbavancin
      • 6.3.6.2. Vancomycin
    • 6.3.7. Others
      • 6.3.7.1. Polymixins
      • 6.3.7.2. Tetracycline and Derivatives
      • 6.3.7.3. Penicillins
      • 6.3.7.4. Macrolides
      • 6.3.7.5. Macrolide-Lincosamide-Streptogramin
      • 6.3.7.6. Rifamycins
      • 6.3.7.7. Fluoroquinolones
      • 6.3.7.8. Nitroimidazole
      • 6.3.7.9. Bismuth Subcitrate Potassium

7. North America Multiple Drug Resistance Bacterial Infection Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
  • 7.3. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 7.4.Multiple Drug Resistance Bacterial Infection Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 7.4.1.1.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 7.4.1.2.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 7.4.1.3.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)

8. UK and European Union Multiple Drug Resistance Bacterial Infection Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
  • 8.3. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 8.4.Multiple Drug Resistance Bacterial Infection Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 8.4.1.1.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 8.4.1.2.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 8.4.1.3.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 8.4.1.4.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 8.4.1.5.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 8.4.1.6.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)

9. Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
  • 9.3. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 9.4.Multiple Drug Resistance Bacterial Infection Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 9.4.1.1.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 9.4.1.2.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 9.4.1.3.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 9.4.1.4.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 9.4.1.5.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 9.4.1.6.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)

10. Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
  • 10.3. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 10.4.Multiple Drug Resistance Bacterial Infection Treatment Market: By Region, 2020-2030, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 10.4.1.1.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 10.4.1.2.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 10.4.1.3.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)

11. Middle East and Africa Multiple Drug Resistance Bacterial Infection Treatment Market, 2020-2030, USD (Million)

  • 11.1. Market Overview
  • 11.2. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
  • 11.3. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 11.4.Multiple Drug Resistance Bacterial Infection Treatment Market: By Region, 2020-2030, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 11.4.1.1.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 11.4.1.2.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Vector, 2020-2030, USD (Million)
        • 11.4.1.3.1. Multiple Drug Resistance Bacterial Infection Treatment Market: By Drug Class, 2020-2030, USD (Million)

12. Company Profile

  • 12.1. Abbott Laboratories, Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Actelion Pharmaceuticals Ltd.
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Albany Molecular Research, Inc.
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Allergan plc.
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. AstraZeneca
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Bayer AG
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Biocon
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Daiichi Sankyo Company
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. GlaxoSmithKline plc.
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Macrolide Pharmaceuticals, Inc.
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Merck & Co, Inc.
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives
  • 12.12. Pfizer, Inc.
    • 12.12.1. Company Overview
    • 12.12.2. Financial Performance
    • 12.12.3. Product Portfolio
    • 12.12.4. Strategic Initiatives
  • 12.13. Sanofi
    • 12.13.1. Company Overview
    • 12.13.2. Financial Performance
    • 12.13.3. Product Portfolio
    • 12.13.4. Strategic Initiatives
  • 12.14. Teva Pharmaceuticals Industries Ltd.
    • 12.14.1. Company Overview
    • 12.14.2. Financial Performance
    • 12.14.3. Product Portfolio
    • 12.14.4. Strategic Initiatives
  • 12.15. Wockhardt
    • 12.15.1. Company Overview
    • 12.15.2. Financial Performance
    • 12.15.3. Product Portfolio
    • 12.15.4. Strategic Initiatives
  • 12.16. Zavante Therapeutics, Inc.
    • 12.16.1. Company Overview
    • 12.16.2. Financial Performance
    • 12.16.3. Product Portfolio
    • 12.16.4. Strategic Initiatives
  • 12.17. Other Notable Players
    • 12.17.1. Company Overview
    • 12.17.2. Financial Performance
    • 12.17.3. Product Portfolio
    • 12.17.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 2 Global Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 3 Global Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 4 Global Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 5 Global Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 6 Global Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 7 Global Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 8 Global Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 9 Global Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 10 Global Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 11 Global Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 12 Global Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 13 North America Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 14 North America Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 15 North America Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 16 North America Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 17 North America Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 18 North America Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 19 North America Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 20 North America Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 21 North America Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 22 North America Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 23 North America Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 24 North America Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 25 U.S. Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 26 U.S. Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 27 U.S. Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 28 U.S. Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 29 U.S. Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 30 U.S. Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 31 U.S. Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 32 U.S. Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 33 U.S. Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 34 U.S. Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 35 U.S. Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 36 U.S. Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 37 Canada Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 38 Canada Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 39 Canada Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 40 Canada Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 41 Canada Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 42 Canada Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 43 Canada Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 44 Canada Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 45 Canada Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 46 Canada Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 47 Canada Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 48 Canada Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 49 Rest of North America Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 50 Rest of North America Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 51 Rest of North America Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 52 Rest of North America Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 53 Rest of North America Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 54 Rest of North America Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 55 Rest of North America Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 56 Rest of North America Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 57 Rest of North America Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 58 Rest of North America Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 59 Rest of North America Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 60 Rest of North America Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 61 UK and European Union Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 62 UK and European Union Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 63 UK and European Union Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 64 UK and European Union Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 65 UK and European Union Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 66 UK and European Union Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 67 UK and European Union Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 68 UK and European Union Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 69 UK and European Union Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 70 UK and European Union Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 71 UK and European Union Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 72 UK and European Union Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 73 UK Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 74 UK Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 75 UK Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 76 UK Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 77 UK Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 78 UK Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 79 UK Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 80 UK Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 81 UK Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 82 UK Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 83 UK Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 84 UK Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 85 Germany Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 86 Germany Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 87 Germany Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 88 Germany Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 89 Germany Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 90 Germany Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 91 Germany Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 92 Germany Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 93 Germany Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 94 Germany Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 95 Germany Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 96 Germany Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 97 Spain Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 98 Spain Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 99 Spain Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 100 Spain Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 101 Spain Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 102 Spain Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 103 Spain Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 104 Spain Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 105 Spain Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 106 Spain Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 107 Spain Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 108 Spain Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 109 Italy Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 110 Italy Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 111 Italy Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 112 Italy Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 113 Italy Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 114 Italy Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 115 Italy Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 116 Italy Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 117 Italy Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 118 Italy Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 119 Italy Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 120 Italy Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 121 France Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 122 France Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 123 France Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 124 France Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 125 France Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 126 France Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 127 France Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 128 France Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 129 France Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 130 France Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 131 France Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 132 France Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 133 Rest of Europe Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 134 Rest of Europe Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 135 Rest of Europe Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 136 Rest of Europe Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 137 Rest of Europe Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 138 Rest of Europe Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 139 Rest of Europe Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 140 Rest of Europe Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 141 Rest of Europe Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 142 Rest of Europe Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 143 Rest of Europe Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 144 Rest of Europe Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 145 Asia Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 146 Asia Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 147 Asia Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 148 Asia Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 149 Asia Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 150 Asia Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 151 Asia Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 152 Asia Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 153 Asia Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 154 Asia Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 155 Asia Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 156 Asia Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 157 China Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 158 China Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 159 China Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 160 China Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 161 China Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 162 China Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 163 China Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 164 China Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 165 China Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 166 China Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 167 China Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 168 China Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 169 Japan Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 170 Japan Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 171 Japan Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 172 Japan Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 173 Japan Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 174 Japan Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 175 Japan Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 176 Japan Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 177 Japan Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 178 Japan Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 179 Japan Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 180 Japan Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 181 India Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 182 India Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 183 India Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 184 India Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 185 India Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 186 India Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 187 India Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 188 India Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 189 India Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 190 India Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 191 India Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 192 India Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 193 Australia Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 194 Australia Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 195 Australia Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 196 Australia Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 197 Australia Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 198 Australia Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 199 Australia Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 200 Australia Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 201 Australia Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 202 Australia Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 203 Australia Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 204 Australia Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 205 South Korea Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 206 South Korea Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 207 South Korea Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 208 South Korea Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 209 South Korea Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 210 South Korea Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 211 South Korea Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 212 South Korea Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 213 South Korea Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 214 South Korea Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 215 South Korea Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 216 South Korea Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 217 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 218 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 219 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 220 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 221 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 222 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 223 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 224 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 225 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 226 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 227 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 228 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 229 Brazil Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 230 Brazil Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 231 Brazil Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 232 Brazil Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 233 Brazil Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 234 Brazil Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 235 Brazil Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 236 Brazil Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 237 Brazil Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 238 Brazil Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)
  • TABLE 239 Brazil Multiple Drug Resistance Bacterial Infection Treatment Market By Glycolipopeptides, 2020-2030, USD (Million)
  • TABLE 240 Brazil Multiple Drug Resistance Bacterial Infection Treatment Market By Others, 2020-2030, USD (Million)
  • TABLE 241 Mexico Multiple Drug Resistance Bacterial Infection Treatment Market By Vector, 2020-2030, USD (Million)
  • TABLE 242 Mexico Multiple Drug Resistance Bacterial Infection Treatment Market By Critical, 2020-2030, USD (Million)
  • TABLE 243 Mexico Multiple Drug Resistance Bacterial Infection Treatment Market By Medium, 2020-2030, USD (Million)
  • TABLE 244 Mexico Multiple Drug Resistance Bacterial Infection Treatment Market By High, 2020-2030, USD (Million)
  • TABLE 245 Mexico Multiple Drug Resistance Bacterial Infection Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 246 Mexico Multiple Drug Resistance Bacterial Infection Treatment Market By Cephalosporin, 2020-2030, USD (Million)
  • TABLE 247 Mexico Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactam, 2020-2030, USD (Million)
  • TABLE 248 Mexico Multiple Drug Resistance Bacterial Infection Treatment Market By Beta Lactamase Inhibitors, 2020-2030, USD (Million)
  • TABLE 249 Mexico Multiple Drug Resistance Bacterial Infection Treatment Market By Oxazolidinone, 2020-2030, USD (Million)
  • TABLE 250 Mexico Multiple Drug Resistance Bacterial Infection Treatment Market By Cyclic Lipopeptide, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Multiple Drug Resistance Bacterial Infection Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Multiple Drug Resistance Bacterial Infection Treatment Market: Quality Assurance
  • FIG. 5 Global Multiple Drug Resistance Bacterial Infection Treatment Market, By Vector, 2021
  • FIG. 6 Global Multiple Drug Resistance Bacterial Infection Treatment Market, By Drug Class, 2021
  • FIG. 7 Global Multiple Drug Resistance Bacterial Infection Treatment Market, By Geography, 2021
  • FIG. 8 Market Geographical Opportunity Matrix - Global Multiple Drug Resistance Bacterial Infection Treatment Market, 2021
  • FIG. 9 Market Positioning of Key Multiple Drug Resistance Bacterial Infection Treatment Market Players, 2021
  • FIG. 10 Global Multiple Drug Resistance Bacterial Infection Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 11 Global Multiple Drug Resistance Bacterial Infection Treatment Market, By Vector, 2021 Vs 2030, %
  • FIG. 12 Global Multiple Drug Resistance Bacterial Infection Treatment Market, By Drug Class, 2021 Vs 2030, %
  • FIG. 13 U.S. Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 Canada Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 Rest of North America Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 UK Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 Germany Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 Spain Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 Italy Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 France Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 Rest of Europe Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 China Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 Japan Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 India Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Australia Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 South Korea Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Rest of Asia Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 Brazil Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 29 Mexico Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 30 Rest of Latin America Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 31 GCC Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 32 Africa Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030
  • FIG. 33 Rest of Middle East and Africa Multiple Drug Resistance Bacterial Infection Treatment Market (US$ Million), 2020 - 2030